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Introduction: The use of bevacizumab combined with chemother-
apy represents a recent advance in clinical oncology for significantly
improving the survival of patients who have non-small cell lung
cancer (NSCLC). There is an unmet need for biomarkers that can
predict response to such treatment and identify patients sensitive to
it. Our study was designed to investigate the predictive value of
intratumoral microvascular density (MVD) in patients with NSCLC
treated with bevacizumab.
Methods: Sixteen patients with NSCLC who underwent chemother-
apy combined with bevacizumab were included into this study.
Paraffin-embedded tumor samples were sectioned and stained im-
munohistochemically for the blood vessel markers CD34 and CD31
to characterize the intratumoral vasculature. A computerized image
analysis program was used to quantitatively calculate the intratu-
moral MVD. Treatment response was evaluated by computed to-
mography scanning.
Results: Two types of blood vessels, undifferentiated (CD31/
CD34) and differentiated (CD34), were identified. A positive
correlation was found between the largest percentage of tumor
shrinkage and the MVD of undifferentiated (CD31/CD34) ves-
sels, with Spearman correlation coefficient being 0.576 (p  0.019).
No correlation between tumor shrinkage and differentiated vessel
MVD (CD34) was found. Moreover, seven of the eight patients
with more undifferentiated vessels showed a partial response, versus
only one of the seven patients with fewer undifferentiated vessels
(p  0.009).
Conclusions: There are two major types of microvessel in lung
cancer vasculature. The MVD of undifferentiated vessels is a
favorable predictor for patients with NSCLC treated with a
chemotherapy regimen plus bevacizumab, with a higher MVD
value correlating with better treatment response. Further studies
are needed to verify the predictive role of MVD in treatment of
NSCLC with bevacizumab.
Key Words: Microvascular density (MVD), Bevacizumab, Chemo-
therapy, Non-small cell lung cancer (NSCLC), Predictive value.
(J Thorac Oncol. 2012;7: 71–75)
Angiogenesis, the process leading to the formation of newblood vessels, is a fundamental requirement for cancer
cell survival, local tumor growth, and development of distant
metastasis.1–3 Angiogenesis is frequently quantified by the
assessment of microvascular density (MVD) in archival tis-
sue, and the degree of MVD assessed by immunohistochem-
istry was thought to have prognostic but not predictive value
in many cancers.4 A meta-analysis showed that a high MVD
in a primary lung tumor was a statistically significant predic-
tor of poor prognosis for survival of surgically treated non-
small cell lung cancer (NSCLC).5 Nevertheless, all tumor
microvessels are not functionally equal. In clear cell renal cell
carcinoma (CCRCC), two distinct types of microvessels were
identified: undifferentiated (CD31/CD34) and differenti-
ated (CD34).6 Moreover, a higher density of undifferenti-
ated microvessels was found to be associated with shorter
survival, whereas a higher density of differentiated microves-
sels significantly correlated with longer survival.6 Therefore,
the undifferentiated blood vessels may be potentially thera-
peutic targets, especially for antiangiogenic drugs. Matura-
tion of blood vessels is marked by the presence of pericytes
surrounding the microvessels. In CCRCC, only some of the
differentiated microvessels are supported by pericytes and
considered to be mature, whereas all the undifferentiated
vessels are immature, without any supporting pericytes.6
Chemotherapy is used to be the standard of care for
patients with advanced stage NSCLC, but its efficacy has
already reached a plateau. Bevacizumab, a humanized anti-
vascular endothelial growth factor (VEGF) monoclonal anti-
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body, inhibits angiogenesis by preventing VEGF from bind-
ing to its receptors.7,8 In lung cancer, the addition of
bevacizumab to standard chemotherapy resulted in a statisti-
cally significant and clinically relevant improvement in pa-
tients outcomes.9 The presumed mechanism of the synergistic
effects was that bevacizumab normalized the vasculature,
resulting in a reduction of interstitial pressure within the
tumor. As a result, vascular permeability was reduced, which
is believed to enhance the delivery of cytotoxic therapy to the
malignant cells.10 That is, perhaps undifferentiated microves-
sels were the actual target of the drug.
Up to now, no predictive markers for anti-VEGF agents
have been identified. The aim of this study was to investigate
whether there were different types of microvessels in NSCLC
and to analyze the relationship between the MVD of tumors
(especially the undifferentiated-vessel MVD) and patients’
response to the treatment with bevacizumab.
PATIENTS AND METHODS
Patient Information
Sixteen patients with stage IIIB or IV adenocarcinoma
of lung, first treated with chemotherapy plus bevacizumab
between April 2007 and June 2009 at the Sun Yat-sen
University Cancer Center (Guangzhou, China), were included
in our study. Written informed consent was obtained from
each patient. Bevacizumab was given intravenously at a dose
of 15 mg/kg on day 1. Patients received paclitaxel (175
mg/m2, day 1) and carboplatin (area under the concentra-
tion time curve 5, day 1) simultaneously. Chemotherapy
was repeated every 21 days for four to six cycles. Patients
continued to receive bevacizumab monotherapy every 3
weeks until evidence of disease progression or unacceptable
toxic effects developed.
Disease Assessment
Full tumor assessment by computed tomography scans
or magnetic resonance imaging scans was performed accord-
ing to the Response Evaluation Criteria in Solid Tumors.
Overall survival was determined from date of treatment until
death or the date the patient was recorded alive of last
follow-up. The largest tumor shrinkage percentage was de-
fined as the largest reduction of the longest diameter of target
lesions in the primary tumors compared with the baseline
level in the computed tomography scans.
Immunohistochemistry
Paraffin-embedded continuous sections of pathologic
samples were obtained by bronchoscopy before therapy.
Immunohistochemical staining for CD31 and CD34 was
performed using a sensitive streptavidin-biotinylated horse-
radish peroxidase complex system (Catalyzed Signal Ampli-
fication System, DAKO, Carpinteria, CA) according to the
manufacturer’s instructions. Primary antibodies were mouse
antihuman CD31 monoclonal antibody (mAb; working dilu-
tion 1:40, JC70A, DAKO) and mouse antihuman CD34 mAb
(1:50, QBEnd10, DAKO). The secondary antibody was bio-
tinylated rabbit antimouse. Normal mouse IgG1 was used as
a substitute for the primary antibody in negative controls.
Slides were steam pretreated in a citrate buffer at pH
6.0 for 30 minutes after deparaffinization. Endogenous per-
oxidase was blocked with 3% hydrogen peroxide and endog-
enous biotin in protein block buffer. Then sections were
incubated at room temperature for 30 minutes with one of the
primary antibodies. After washes, the sections were incubated
at room temperature with the secondary antibody for 15
minutes. Finally, sections were incubated with streptavidin-
biotin complex for 15 minutes.
Computerized Quantification of Microvessel
Density
The quantification of immunohistochemically stained
vessels was performed using a computerized image analysis
program.6 Briefly, for CD34-stained slides, five areas show-
ing the highest vascular density (hotspots) were spectrally
imaged using a CRi Nuance camera system (Woburn, MA).
The same five areas were then located on the CD31-stained
slides and imaged. The resulting image cubes were then
converted to optical density units and were mathematically
unmixed into either their individual CD34 and counterstain
components or their CD31 and counterstain components,
using spectrums deduced from control specimens and saved
in spectral libraries. The components were then pseudocol-
ored and converted to pseudofluorescent format for quantifi-
cation. The unmixed images were quantified using Imagine
analysis software developed at Van Andel Research Insti-
tute.6,11 A standard threshold was applied to all the images to
select for vessels, and vessel count and total vessel pixels
were determined. The count of undifferentiated microvessels
was obtained by subtracting the CD34 vessel count from the
CD31 vessel count.
Statistical Analysis
Spearman rank correlation coefficients were calculated
and then tested between largest tumor shrinkage and MVD.
The correlations between MVD and tumor response were
assessed by the 2 test. The Kaplan-Meier method was used
to estimate survival, and survival differences were analyzed
by the log-rank test.
RESULTS
Patient Characteristics
Sixteen patients were included in our study; one of
them with incomplete clinical data was excluded in the
clinical analysis. As listed in Table 1, the ages of patients
ranged from 25 to 70 years (median, 51 years); six were
women (40%) and five were smokers (33%). All the patients
had adenocarcinoma with Eastern cooperative oncology
group performance status 0 to 1. All patients received first-
line treatment with chemotherapy plus bevacizumab.
Response and Survival
Eight patients had a partial clinical response after the
treatment, five had stable disease, and two had disease pro-
gression, yielding a response rate of 53.3%. The median
progression-free survival was 7.83 (5.16–10.50) months, and
the overall survival was 12.4 (8.1–16.8) months.
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Two Types of Tumor Vessels were Found in
NSCLC
The formalin-fixed paraffin-embedded tissues of all the
16 patients were available for immunohistochemical analysis.
More blood vessels were stained by anti-CD31 antibody
versus anti-CD34 antibody (Figure 1). CD31 is expressed in
both differentiated and undifferentiated endothelial cells,
whereas CD34 is only expressed in differentiated endothelial
cells.12 Therefore, there were two types of blood vessels in
NSCLC: differentiated vessels (CD34) and undifferentiated
vessels (CD31/CD34). The median count of each type of
vessel was used as the cutoff point to divide the patients into
high- and low-MVD groups.
MVD and Tumor Shrinkage
We analyzed the relationship between MVD and the
largest tumor shrinkage percentage in the primary tumors
(change from baseline). There was a positive correlation
between undifferentiated-vessel MVD and the largest tumor
shrinkage; Spearman correlation coefficient equaled 0.576
TABLE 1. Characteristics of 15a Enrolled Patients


















a One patient was excluded from the analysis because of incomplete clinical data.
ECOG, Eastern cooperative oncology group.
FIGURE 1. Distinguishing characteristics of two types of vessels in lung adenocarcinoma corresponding to different drug re-
sponse: non-small cell lung cancer (NSCLC) samples from a partial-response patient and a progressive-disease patient are pre-
sented. Two continuous sections of each tumor were immunohistochemically stained with antibodies against CD31 and
CD34, respectively. Most of the undifferentiated (CD31/CD34) vessels have no (or a small) lumen, a thicker vessel wall,
and smaller size relative to differentiated (CD34) vessels. The undifferentiated vessel count was 80 in the field of the tumor
from the partial response patient, and it was 24 in the progressive disease patient.
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(p  0.019) (Figure 2). No significant correlation was found
between differentiated-vessel MVD and largest tumor shrink-
age percentage.
The Correlation between MVD and Patient
Outcomes in NSCLC
The median undifferentiated-vessel MVD was 25
vessels/field. A high undifferentiated-vessel MVD (25)
was observed in eight patients, and seven of those eight
patients showed partial response to the treatment. In the
seven patients with low undifferentiated-vessel MVD
(25), only one patient had a partial response. Using 2
tests in univariate models, the difference was statistically
significant (p  0.009).
The difference in median survival time between pa-
tients with high versus low undifferentiated-vessel MVD was
not statistically significant (11.1 months and 16.2 months,
respectively; p  0.21). The difference in progression-free
survival between these two groups also showed no statistical
significance (6.53 and 8.77 months, respectively; p  0.40).
The median differentiated-vessel (CD34) MVD count
was 49 vessels/field. No significant correlation was found
between differentiated-vessel MVD and patient outcome.
DISCUSSION
In CCRCC, the value of microvessel density as a
predictor of prognosis is controversial. Some reports have
shown a positive correlation between MVD and progno-
sis,13–15 whereas others have shown an inverse relation-
ship.16,17 When we classified the intratumoral blood vessels
based on differential expressions of blood vessel markers,
two distinct types of microvessels were identified, and the
two types demonstrated contrasting prognostic implications.6
The results suggest that a refined classification of tumor
vasculature is necessary for further exploration into the role
of angiogenesis.
A systematic review5 of NSCLC in 2002 showed that
high MVD is a poor prognostic factor for survival, regardless
of what antibody (factor VIII, CD34 or CD31) used for
assessing the vessel count. Nevertheless, as indicated by the
authors, the review included only NSCLC treated by surgery;
therefore, the conclusions could not be extrapolated to pa-
tients with metastatic NSCLC, whom are mainly treated
using combination chemotherapy. Further, the use of panen-
dothelial cell markers, such as CD31 or CD34 alone, reflects
the presence of blood vessels but does not give an indication
of the functional status of the tumor vasculature.
The complexity of tumor vasculature has been recog-
nized in some solid tumors.18,19 Multiple cell types may
contribute to the formation of tumor vasculature, including
bone marrow-derived circulating stem cells, tissue-resident
normal stem cells, and tumor stem cells.20 The variety of
endothelial cell origin may result in the discrepancy of
endothelial differentiation. Moreover, the tumor vasculature
complexity implies that antiangiogenic therapy could induce
various responses due to the variety of target components. In
fact, distinct responses have been observed in blocking
VEGF signaling, because VEGF-specific antibodies only lead
to the regression of immature vessels (without pericytes) but
do not affect the mature vessels (with pericytes).21 It has also
been reported that proliferating endothelial cells in tumor
vessels might associate with the action of a particular anti-
angiogenic agent.22
Bevacizumab is a recombinant humanized monoclonal
antibody that binds to the circulating VEGF-A ligand. It is the
only antiangiogenic agent approved by the United States
Food and Drug Administration for first-line treatment of
NSCLC. Jubb et al.23 reported that in metastatic colon and
rectal cancer, the MVD of CD34 vessels in primary tumors
does not predict response to bevacizumab. This could be
explained by the fact that a significant proportion of those
differentiated vessels are actually mature vessels supported
by pericytes, and the mature vessels are resistant to VEGF
targeting therapy. Therefore, we wondered whether there are
undifferentiated (CD31/CD34) vessels in NSCLC similar
to those in CCRCC and whether their MVD could be a better
predictor of response to bevacizumab therapy.
In this study, we identified two types of blood vessels
in NSCLC, namely, differentiated (CD34) vessels and
undifferentiated (CD31/CD34) vessels. Consistent with
the finding of Jubb et al., differentiated vessels did not
predict response to bevacizumab in NSCLC. Nevertheless,
there was a positive correlation between undifferentiated-
vessel MVD and the largest tumor shrinkage after con-
ventional chemotherapy plus bevacizumab (p  0.019).
Moreover, seven of the eight patients with high undifferen-
tiated-vessel MVD showed a partial response, versus only
one of seven patients who had low undifferentiated-vessel
MVD (p  0.009).
Our study showed no survival benefit in the patients
with high undifferentiated-vessel MVD; there may be several
reasons for this finding. First, after initial response to bevaci-
zumab treatment, patients with higher undifferentiated-vessel
MVD may experience quicker tumor relapse and more inva-
FIGURE 2. Relationship between undifferentiated-vessel
microvascular density (MVD) and tumor shrinkage (Spear-
man rank correlation): 16 patients with stage IIIB and IV ad-
enocarcinoma of lung who received first-line treatment with
chemotherapy plus bevacizumab were available for analyses.
Chemotherapy was repeated every 21 days for 4–6 cycles,
and bevacizumab was continued every 3 weeks until evi-
dence of disease progression or unacceptable toxic effects
developed.
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sive metastatic disease, as seen in VEGF-targeted therapy.24
Second, in addition to vasculature normalization, bevaci-
zumab has a direct antiangiogenesis effect in human tu-
mors,7,8 which cannot be predicted by undifferentiated-vessel
MVD. Finally, our small sample size may not be sufficient to
demonstrate a statistically significant survival difference. All
these issues need further study.
In conclusion, we have for the first time identified
differentiated and undifferentiated vessels in NSCLC and
have shown that the undifferentiated CD31/CD34 ves-
sels are a favorable predictor for treatment response to
chemotherapy regimen including bevacizumab. Consider-
ing the small sample size in our study, these findings
warrant further validation using a larger cohort and more
rigid controls.
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